Many cases of hospital-acquired infections and healthcare-associated illnesses are attributable to C. difficile infection (CDI). Although standard-of-care antibiotics are relatively effective, the virulence of CDI has increased and standard antibiotic therapies are associated with a risk of recurrence. Due to the high rates of CDI recurrence, risk of mortality, need for prolonged hospitalization, and financial burden that these infections impose on healthcare systems, CDI represents an important segment of the hospital antibiotic market. Because CDI has been recognized as a condition linked to the disruption of the natural flora, interest is growing in restoring and maintaining a healthy and diverse intestinal microbiome, and the utility of narrow-spectrum agents and microbiome-based therapies as treatment strategies is being explored. Thought leaders note that preventive strategies and treatments for severe and recurrent CDI remain critical areas of unmet need in this market.
Market covered: United States, France, Germany, Italy, Spain, and the United Kingdom.
Primary research: Six country-specific interviews with C. difficile infection specialists.
Epidemiology: Diagnosed events of CDI by country, recurrence, and severity of disease.
Emerging therapies: Phase III/PR: 6, Phase II: 2; coverage of select preclinical and Phase I products.
Market forecast: Drug-level sales and patient share of key C. difficile infection therapies in 2026. Sales and patient share of current therapies in the U.S. and EU5 in 2016.
Key companies: Merck, Rebiotix, Seres Therapeutics, Summit Therapeutics
Key drugs: vancomycin, metronidazole, fidaxomicin, bezlotoxumab, fecal microbiota transplantation, SER-109, RBX2660, ridinilazole